Cosopt and Tafluprost drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cosopt (dorzolamide hydrochloride; timolol maleate) and Tafluprost (tafluprost). Common drug interactions include insomnia among females and flatulence among males.

The phase IV clinical study analyzes what interactions people have when they take Cosopt and Tafluprost. It is created by eHealthMe based on reports of 34 people who take the same drugs from the FDA, and is updated regularly.

What is Cosopt?

Cosopt has active ingredients of dorzolamide hydrochloride; timolol maleate. It is often used in glaucoma. eHealthMe is studying from 9,029 Cosopt users. Check the latest studies of Cosopt.

What is Tafluprost?

Tafluprost has active ingredients of tafluprost. eHealthMe is studying from 459 Tafluprost users. Check the latest studies of Tafluprost.



On Jul, 20, 2026

34 people who take Cosopt and Tafluprost together, and have interactions are studied.

Cosopt and Tafluprost drug interactions.

What are the common drug interactions of Cosopt and Tafluprost, by gender? *:

female:

  1. Insomnia (sleeplessness)
  2. Anaemia (lack of blood)
  3. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  4. Basedow's disease (autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones)
  5. Blindness unilateral
  6. Bradycardia (abnormally slow heart action)
  7. C-reactive protein increased
  8. Diarrhoea
  9. Diplopia (double vision)
  10. Dyspnoea (difficult or laboured respiration)

male:

  1. Flatulence (flatus expelled through the anus)
  2. Prostatic specific antigen increased
  3. Monoplegia (a paralysis of a single limb)
  4. Myositis (inflammation of the muscles)
  5. Vomiting
  6. Drug ineffective
  7. Abdominal distension
  8. Alanine aminotransferase increased
  9. Aspartate aminotransferase increased
  10. Cataract (clouding of the lens inside the eye)

What are the common drug interactions of Cosopt and Tafluprost, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Basedow's disease (autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones)
  2. Blindness unilateral
  3. Bradycardia (abnormally slow heart action)
  4. C-reactive protein increased
  5. Diplopia (double vision)
  6. Endocrine ophthalmopathy (increased water content of retroocular orbital tissues; associated with thyroid disease, usually hyperthyroidism)
  7. Fatigue (feeling of tiredness)
  8. Feeling hot
  9. Fungal infection
  10. Headache (pain in head)

40-49:

  1. Hyperglycaemia (high blood sugar)
  2. Hyperkalaemia (damage to or disease of the kidney)
  3. Lactic acidosis (low ph in body tissues)
  4. Oropharyngeal discomfort (pain or irritation of oropharynx)
  5. Palpitations (feelings or sensations that your heart is pounding or racing)

50-59:

  1. Abdominal pain
  2. Constipation
  3. Flatulence (flatus expelled through the anus)
  4. Hallucination (an experience involving the perception of something not present)
  5. Impaired gastric emptying
  6. Vomiting
  7. Alopecia (absence of hair from areas of the body)
  8. Back pain
  9. Blood glucose decreased
  10. Eye disorder

60+:

  1. Anaemia (lack of blood)
  2. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  3. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  4. Injection site cellulitis (injection site inflammation)
  5. Monoplegia (a paralysis of a single limb)
  6. Myositis (inflammation of the muscles)
  7. Prostatic specific antigen increased
  8. Drug ineffective
  9. Visual impairment
  10. Abdominal distension

What are the existing conditions these people have? *

  1. High Blood Pressure: 5 people, 14.71%
  2. Stress And Anxiety: 3 people, 8.82%
  3. Stable Angina (a constant chest pain): 3 people, 8.82%
  4. Platelet Count Increased: 3 people, 8.82%
  5. Malignant Melanoma (skin cancer rises from melancytes): 3 people, 8.82%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 8.82%
  7. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 8.82%
  8. Pain: 2 people, 5.88%
  9. Lower Urinary Tract Symptoms: 2 people, 5.88%
  10. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Cosopt and Tafluprost?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cosopt and Tafluprost:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cosopt:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tafluprost:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cosopt and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tafluprost and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on dorzolamide hydrochloride; timolol maleate and tafluprost (the active ingredients of Cosopt and Tafluprost, respectively), and Cosopt and Tafluprost (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: